logo
  

Eaton Corp. Q4 Profit Tops Estimates - Quick Facts

Eaton Corp. plc (ETN) reported fourth-quarter net income to shareholders of $581 million or $1.23 per share, compared to $479 million or $1.00 per share, prior year. Operating earnings per share was $1.27, for the quarter.

On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $1.20 for the quarter. Analysts' estimates typically exclude special items.

Net sales increased to $5.57 billion from $5.53 billion last year. Analysts expected revenue of $5.59 billion for the quarter.

In 2015, the company anticipates organic revenues will grow between 3 and 4 percent. The company expects the impact of negative foreign exchange to be approximately 4 percent. Eaton expects 2015, operating earnings per share, which exclude an estimated $45 million of charges to integrate recent acquisitions, to be between $4.75 and $5.05 per share. Excluding the sizeable impact from expected negative foreign exchange during 2015, operating earnings per share would be about $0.20 higher, the company noted. Analysts expect the company to report full year earnings per share of $4.97.

For the first quarter, the company expects operating earnings per share, which exclude an estimated $15 million of charges to integrate recent acquisitions, to be between $0.95 and $1.05 per share. Analysts expect the company to report first-quarter earnings per share of $1.10.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT